J&J reviews constructive information for Erda-iDRS in bladder most cancers
Johnson & Johnson (J&J) has reported encouraging outcomes from a Section I research of the investigational intravesical drug supply system Erda-iDRS (erdafitinib).
The research focuses on intermediate- and high-risk non-muscle-invasive bladder most cancers (NMIBC) sufferers who exhibit sure adjustments within the fibroblast progress issue receptor (FGFR).
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra data
The multicenter, open-label research met its main security endpoint, demonstrating sturdy, full responses in intermediate-risk sufferers and inspiring recurrence-free outcomes in high-risk illness.
Information had been offered on the European Affiliation of Urology 2026 Annual Assembly.
Erda-iDRS delivers erdafitinib instantly into the bladder through intravesical administration over three months, enabling localized remedy to reduce systemic publicity and unwanted side effects related to oral administration.
On November 3, 2025, 62 intermediate-risk relapsed NMIBC sufferers and 26 high-risk relapsed Bacillus Calmette-Guérin-experienced NMIBC sufferers obtained Erda-iDRS.
Security was the first endpoint, whereas secondary endpoints assessed full response price and period for intermediate-risk instances and recurrence-free survival for high-risk instances.
In average-risk sufferers receiving nonsurgical remedy for seen tumors, the whole response price was 89% throughout the preliminary remedy interval. The median period of full response was 18 months, with a median follow-up of 18 months. 49% of those sufferers are nonetheless monitored.
Amongst high-risk sufferers handled with Erda-iDRS, the median recurrence-free survival was 20 months and the recurrence-free survival price at 12 months was 83%. The median follow-up on this group was 24 months, with 31% remaining underneath commentary.
The remedy gave the impression to be usually effectively tolerated and no dose-limiting toxicities had been reported. Native adversarial reactions had been the most typical, together with hematuria and dysuria.
4 sufferers skilled grade three or larger adversarial occasions associated to remedy; eight sufferers discontinued as a result of unwanted side effects; and two sufferers had severe treatment-related adversarial occasions.
Pharmacokinetic information confirmed sustained drug ranges in urine and minimal systemic publicity with out noticed hyperphosphatemia.
Christopher Cutie, bladder most cancers illness chief at J&J, stated: “For sufferers with FGFR-modified non-muscle invasive bladder most cancers, care has not traditionally been guided by precision-based approaches.
“The excessive and sturdy full response demonstrated with Erda-iDRS underlines the chance to supply these sufferers with focused remedy. Introducing a biology-based method at earlier phases of this illness has the potential to alter the best way these sufferers are handled.”
Final month, J&J reported new findings from the QUASAR long-term extension research of Tremfya (guselkumab) for ulcerative colitis (UC).
